George Woody, MD
Department of Psychiatry
University of Pennsylvania
The usual treatment for opioid-addicted youth is detoxification and counseling. Some treatment providers are reluctant to use opioid agonist medications in this population, especially for long-term opioid maintenance. This study compared Bup/Nx treatment for 9 weeks and taper for 3 weeks to treatment as usual (Bup/Nx detox for 2 weeks). Both arms received counseling for 12 weeks.
Results of the study showed that continuing Bup/Nx for 12 weeks vs. 2 weeks improved outcomes. During weeks 1 through 12, patients in the 12-week Bup/Nx group reported less opioid use (P<.001), better retention (70% vs. 21%; p<.0001), less injecting (P=.01), and less use of cocaine (p<.001) and marijuana (p<.001). Continuing treatment with Bup/Nx for 12 weeks appears to be safe in opioid addicted adolescents and young adults.
Primary Outcomes Article: Woody G, et al. Extended vs. short-term buprenorphine/naloxone for treatment of opioid-addicted youth: A randomized trial. Journal of the American Medical Association 2008;300(17):2003-2011. [get article]
- CTN-0010-A-1: Cost-Effective Analysis (CEA) in the CTN: Bup/Nal Treatment for Opioid Addicted Youth
- CTN-0010-A-2: Comorbid Conditions in Adolescents with Opioid Versus Alcohol/Marijuana Use Disorders
- CTN-0010 Study Protocol
- Publications in the Library about CTN-0010
- Study data from NIDA Data Share
- Blending Team Product: Buprenorphine Treatment for Young Adults
- Blending Team Product: Buprenorphine Suite
- ClinicalTrials.gov (NCT00078130)
- NIDA protocol page
All Participating Nodes: